Koji Matsumoto

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

Hidetoshi Hayashi, Takayasu Kurata, Yuichi Takiguchi et al. · Journal of Clinical Oncology · 2019 · 168 citations

Medicine, Oncology, Pharmacology +16

Patients with ovarian carcinoma upstaged to Stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients

Takashi Onda, Hiroyuki Yoshikawa, Toshiharu Yasugi et al. · Cancer · 1998 · 134 citations

Medicine, Oncology, Surgery +16

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto et al. · Journal of Clinical Oncology · 2023 · 127 citations · Full text

Medicine, Oncology, Pharmacology +17